LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2026. Recent Business Highlights: Ultra-Low temperature ablation (“ULTA”) featured in four podium presentations at the VT Symposium 2026 held October 9-10 in New York, with topics spanning clinical experience, comp
See full post here as originally published on this site



